Physicians' Academy for Cardiovascular Education

Kidney disease & CVD

Follow the news, literature, and elearning on new developments in the management of Kidney disease and CVD
4 things to know about CKD and SGLT2i - lecture 3 out of 4

A call to action: optimizing treatment in CKD

10' education - Mar. 22, 2023 - Prof. Meg Jardine, MD, PhD

Early eGFR decline after transitioning to ARNI not associated with adverse outcomes

3' education - Mar. 6, 2023 - Safia Chatur, MD
4 things to know about CKD and SGLT2i - lecture 2 out of 4

When and how to initiate SGLT2i in CKD

10' education - Feb. 14, 2023 - Prof. David Wheeler, MD
4 things to know about CKD and SGLT2i - lecture 1 out of 4

What is the evidence of SGLT2i in CKD?

10' education - Feb. 7, 2023 - Prof. Hiddo L. Heerspink, PhD

Inflammation as a new target in CV risk reduction

10' education - Dec. 13, 2022 - Prof. Paul Ridker, MD

Optimizing GDMT in HFrEF and management of hyperkalemia

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD

Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD

3' education - Nov. 7, 2022 - David Preiss, PhD

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

Discussion - Rethinking the role of nephrologists in prevention of CKD - The opportunity of early risk identification

10' education - July 6, 2022 - Prof. Christoph Wanner, MD, Rikke Borg, MD, PhD, and prof. Kamlesh Khunti, MD, PhD

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD

Why is early screening and risk identification of CKD in diabetes important?

10' education - July 6, 2022 - Rikke Borg, MD, PhD

Barriers for preventing CKD in patients with diabetes

10' education - June 28, 2022 - Prof. Christoph Wanner, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

Cardiorenal effects of nonsteroidal MRAs in patients with CKD and T2DM

10' education - June 7, 2022 - Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD and María José Soler, MD, PhD

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD

Which patients benefit from potassium binders?

10' education - Feb. 15, 2022 - Kevin Damman, MD, PhD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

IL-6 inhibition reduces neutrophil-lymphocyte ratio in patients with CKD and elevated hsCRP

Literature - Mar. 22, 2023 - Adamstein NH, et al. - JAMA Cardiol. 2023

A secondary analysis of the RESCUE trial investigated whether IL-6 inhibition with ziltivekimab, a novel therapeutic monoclonal antibody against IL-6, changes the neutrophil-lymphocyte ratio (NLR) in patients with CKD and elevated hsCRP.

A call to action: optimizing treatment in CKD

10' education - Mar. 22, 2023 - Prof. Meg Jardine, MD, PhD
To what extent does the evidence of RCTs on use of SGLT2i in patients with CKD translate to clinical practice? Meg Jardine gives an overview of studies and provides tools to increase uptake of SGLT2I in this field.

4 things to know about CKD and SGLT2i To what extent does the evidence of RCTs on use of SGLT2i in patients with CKD translate to clinical practice? Meg Jardine gives an overview of studies and provides tools to increase uptake of SGLT2I in this field.

Treatment effects of ARNI in HF independent of eGFR decline during run-in phase

Literature - Mar. 20, 2023 - Chatur S, Claggett BL, McCausland FR, et al. - J Am Coll Cardiol. 2023

Patients with HF may experience a transient decline in eGFR of up to 15-20% after initiation of sacubitril/valsartan. But how does this affect treatment effects? This post hoc analysis of the PARADIGM-HF and PARAGON-HF study offers more insight.

Beneficial effects of nonsteroidal MRA on mortality in patients with CKD and T2DM

Literature - Mar. 15, 2023 - Filippatos G, et al. - Eur Heart J Cardiovasc Pharmacother. 2023

In the prespecified FIDELITY analysis, the authors investigated the causes of mortality in patients with CKD and T2DM treated with the nonsteroidal MRA finerenone or placebo.

SGLT2i improves CV outcomes in patients with HFmrEF or HFpEF regardless of kidney function

Literature - Mar. 14, 2023 - Mc Causland FR, et al. - JAMA Cardiol. 2023

In this prespecified analysis of the DELIVER trial, the authors evaluated whether baseline kidney function modified the effect of the SGLT2i dapagliflozin on CV improvement in patients with HFmrEF or HFpEF, and determined the effect of dapagliflozin treatment on kidney outcomes.

Early eGFR decline after transitioning to ARNI not associated with adverse outcomes

3' education - Mar. 6, 2023 - Safia Chatur, MD

ACC.23 "Early treatment-related eGFR decline should not stall uptitration or impede continuation of ARNI", says Safia Chatur. She lists the findings of an analysis of PARADIGM-HF and PARAGON-HF in patients with HF.

Expanded indication for non-steroidal MRA in EU for broad range of patients with CKD and T2DM

News - Mar. 1, 2023

The European Commission approved a label update to extend the indication of finerenone to early stages of CKD in patients with T2DM.

Cardiorenal benefits of nonsteroidal MRA not modified by HbA1c levels, HbA1c variability, diabetes duration, or insulin use

Literature - Feb. 23, 2023 - McGill JB, et al. - Diabetes Obes Metab. 2023

In a post-hoc analysis of the pooled FIDELITY dataset, finerenone’s cardiorenal benefits over placebo in T2DM patients with CKD were not modified by these 4 factors. Notably, HbA1c variability was associated with greater risk of cardiorenal outcomes.

When and how to initiate SGLT2i in CKD

10' education - Feb. 14, 2023 - Prof. David Wheeler, MD
**4 things to know about CKD and SGLT2i** Prof. David Wheeler illustrates which patients with CKD should be treated with SGLT2 inhibitors using three case studies.

4 things to know about CKD and SGLT2i Prof. David Wheeler illustrates which patients with CKD should be treated with SGLT2 inhibitors using three case studies.

What is the evidence of SGLT2i in CKD?

10' education - Feb. 7, 2023 - Prof. Hiddo L. Heerspink, PhD
**4 things to know about CKD and SGLT2i** Prof. Heerspink explains in this video that SGLT2i slow the progression of CKD, and reduce the risk of kidney failure and acute kidney injury.

4 things to know about CKD and SGLT2i Prof. Heerspink explains in this video that SGLT2i slow the progression of CKD, and reduce the risk of kidney failure and acute kidney injury.

Effect of SGLT2 inhibitor on CV death or HF hospitalization in HFpEF independent of SBP

Literature - Jan. 30, 2023 - Böhm M, et al. - Eur Heart J. 2022

The SGLT2 inhibitor empagliflozin reduces the risk of cardiovascular death or first hospitalization for HF in patients with HF and an LVEF >40%, compared with placebo. It is unclear whether this effect is modified by SBP.

Lower LDL‐c levels associated with CV and renal benefits in moderate CKD under statin treatment

Literature - Jan. 16, 2023 - Yen CL et al. - J Am Heart Assoc. 2022

A Taiwanese observational study evaluated CV and renal outcomes in statin-treated patients with stage 3 CKD across different LDL‐c levels.